Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral lichen planus

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral... The aim of this study was to evaluate the safety and efficacy of Bacillus Calmette‐Guerin, polysaccharide nucleic acid (BCG‐PSN) therapy in the treatment of oral and cutaneous LP. Twenty‐four LP patients were included in this study and classified randomly into; Oral LP group (OLP), 11 patients and Cutaneous LP group (CLP), 13 patients. All patients received intradermal injections of BCG‐PSN, twice weekly for three weeks. Patients with complete response were followed up for 3 months. The assessment in OLP was based on the reduction in the treated area, (Reticulation/Erythema/Ulceration) REU scoring system and numerical rating scale (NRS). CLP evaluated by the response to treatment as (complete, partial and no response) and visual analogue scale (VAS). There were highly significant differences in the diminution of lesion areas (p < .006), NRS scores (p < .001), REU score (p < .011), and VAS (p < .001) after treatment. The majority of patients achieved complete response after 3‐week management. The BCG‐PNS is safe and effective in the treatment of oral and cutaneous LP. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Dermatologic Therapy Wiley

Bacillus Calmette‐Guerin, polysaccharide nucleic acid in the treatment of cutaneous and oral lichen planus

Loading next page...
 
/lp/wiley/bacillus-calmette-guerin-polysaccharide-nucleic-acid-in-the-treatment-bU2LKlkMgC

References (22)

Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1396-0296
eISSN
1529-8019
DOI
10.1111/dth.12591
pmid
29405515
Publisher site
See Article on Publisher Site

Abstract

The aim of this study was to evaluate the safety and efficacy of Bacillus Calmette‐Guerin, polysaccharide nucleic acid (BCG‐PSN) therapy in the treatment of oral and cutaneous LP. Twenty‐four LP patients were included in this study and classified randomly into; Oral LP group (OLP), 11 patients and Cutaneous LP group (CLP), 13 patients. All patients received intradermal injections of BCG‐PSN, twice weekly for three weeks. Patients with complete response were followed up for 3 months. The assessment in OLP was based on the reduction in the treated area, (Reticulation/Erythema/Ulceration) REU scoring system and numerical rating scale (NRS). CLP evaluated by the response to treatment as (complete, partial and no response) and visual analogue scale (VAS). There were highly significant differences in the diminution of lesion areas (p < .006), NRS scores (p < .001), REU score (p < .011), and VAS (p < .001) after treatment. The majority of patients achieved complete response after 3‐week management. The BCG‐PNS is safe and effective in the treatment of oral and cutaneous LP.

Journal

Dermatologic TherapyWiley

Published: Jan 1, 2018

Keywords: ; ;

There are no references for this article.